JP2008501308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008501308A5 JP2008501308A5 JP2006554221A JP2006554221A JP2008501308A5 JP 2008501308 A5 JP2008501308 A5 JP 2008501308A5 JP 2006554221 A JP2006554221 A JP 2006554221A JP 2006554221 A JP2006554221 A JP 2006554221A JP 2008501308 A5 JP2008501308 A5 JP 2008501308A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- antibody
- mab
- cancer
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060006698 EGF receptor Proteins 0.000 claims description 183
- 102000001301 EGF receptor Human genes 0.000 claims description 167
- 210000004027 cell Anatomy 0.000 claims description 66
- 102000005962 receptors Human genes 0.000 claims description 63
- 108020003175 receptors Proteins 0.000 claims description 63
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 41
- 239000003446 ligand Substances 0.000 claims description 36
- 239000012634 fragment Substances 0.000 claims description 17
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 239000000539 dimer Substances 0.000 description 33
- 102100032768 Complement receptor type 2 Human genes 0.000 description 29
- 230000004913 activation Effects 0.000 description 21
- 230000003993 interaction Effects 0.000 description 21
- 238000006471 dimerization reaction Methods 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 17
- 230000009257 reactivity Effects 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 102000020233 phosphotransferase Human genes 0.000 description 15
- 235000018417 cysteine Nutrition 0.000 description 14
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 13
- 239000000178 monomer Substances 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 239000004227 calcium gluconate Substances 0.000 description 10
- 230000007704 transition Effects 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 230000011664 signaling Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000011533 pre-incubation Methods 0.000 description 7
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 101150039808 Egfr gene Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 238000013391 scatchard analysis Methods 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001908 autoinhibitory effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008876 conformational transition Effects 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 108700021358 erbB-1 Genes Proteins 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 108010068542 Somatotropin Receptors Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- IYBKWXQWKPSYDT-UHFFFAOYSA-L ethylene glycol disuccinate bis(sulfo-N-succinimidyl) ester sodium salt Chemical compound [Na+].[Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCC(=O)OCCOC(=O)CCC(=O)ON1C(=O)C(S([O-])(=O)=O)CC1=O IYBKWXQWKPSYDT-UHFFFAOYSA-L 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- BQVCCPGCDUSGOE-UHFFFAOYSA-N phenylarsine oxide Chemical compound O=[As]C1=CC=CC=C1 BQVCCPGCDUSGOE-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000033300 receptor internalization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54660204P | 2004-02-20 | 2004-02-20 | |
| US58462304P | 2004-07-01 | 2004-07-01 | |
| PCT/US2005/005155 WO2005081854A2 (en) | 2004-02-20 | 2005-02-18 | Egf receptor epitope peptides and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274098A Division JP6045147B2 (ja) | 2004-02-20 | 2011-12-15 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008501308A JP2008501308A (ja) | 2008-01-24 |
| JP2008501308A5 true JP2008501308A5 (cg-RX-API-DMAC7.html) | 2011-06-30 |
Family
ID=34915579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006554221A Pending JP2008501308A (ja) | 2004-02-20 | 2005-02-18 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
| JP2011274098A Expired - Lifetime JP6045147B2 (ja) | 2004-02-20 | 2011-12-15 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011274098A Expired - Lifetime JP6045147B2 (ja) | 2004-02-20 | 2011-12-15 | Ｅｇｆレセプターエピトープペプチドおよびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7767792B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1722808B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2008501308A (cg-RX-API-DMAC7.html) |
| KR (2) | KR101280267B1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU2005216082B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2556632C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2536974T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005081854A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP1392359B2 (en) | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| DK1399484T3 (da) * | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
| EP2135879A3 (en) * | 2002-06-28 | 2010-06-23 | Domantis Limited | Ligand |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| US7767792B2 (en) * | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| US20070009972A1 (en) * | 2005-02-16 | 2007-01-11 | Ginger Chao | Epidermal growth factor receptor polypeptides and antibodies |
| RU2473560C2 (ru) * | 2005-11-02 | 2013-01-27 | Дьюк Юниверсити | Совместная химиотерапия и иммунотерапия |
| TW200730539A (en) * | 2005-12-01 | 2007-08-16 | Domantis Ltd | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| JP2009532358A (ja) * | 2006-03-31 | 2009-09-10 | マサチューセッツ・インスティテュート・オブ・テクノロジー | 突然変異型ｅｇｆ受容体を発現する腫瘍の治療 |
| WO2008033495A2 (en) * | 2006-09-15 | 2008-03-20 | Life Science Pharmaceuticals | Method for detecting and treating skin disorders |
| US9090693B2 (en) | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| WO2008103475A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Somatic hypermutation systems |
| CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
| USRE47534E1 (en) * | 2007-04-23 | 2019-07-23 | Ramot At Tel Aviv University Ltd. | System, method and a computer readable medium for providing an output image |
| JP2010528647A (ja) | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| CN101896503B (zh) * | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| WO2009023266A1 (en) * | 2007-08-14 | 2009-02-19 | Ludwig Institute For Cancer Research | Generation of antibodies to cell-surface receptors and cancer-associated proteins including egfr family members |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| AR069495A1 (es) | 2007-11-30 | 2010-01-27 | Glaxo Group Ltd | Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis) |
| WO2009149094A2 (en) * | 2008-06-02 | 2009-12-10 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Cytotoxic t cell defined egfr peptide and an optimized derivative peptide |
| JP2010006705A (ja) * | 2008-06-13 | 2010-01-14 | Atlas Antibodies Ab | Ｈｅｒ２サブセット |
| US20100004306A1 (en) * | 2008-06-18 | 2010-01-07 | Abbott Laboratories | PIGF-1 Assay and kits and components thereof |
| WO2009155381A1 (en) * | 2008-06-18 | 2009-12-23 | Abbott Laboratories | P/gf-1 companion diagnostic methods and products |
| US8741287B2 (en) * | 2008-06-18 | 2014-06-03 | Abbott Laboratories | PlGF-1 assay and kits and components thereof |
| US20100189727A1 (en) * | 2008-12-08 | 2010-07-29 | Tegopharm Corporation | Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| CA2749339A1 (en) | 2009-01-12 | 2010-07-15 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| CN102481341B (zh) | 2009-02-23 | 2017-05-17 | 希托马克斯医疗有限公司 | 蛋白原及其使用方法 |
| WO2011035465A1 (zh) * | 2009-09-22 | 2011-03-31 | 上海市肿瘤研究所 | 特异性结合蛋白及其使用 |
| CN103539840B (zh) * | 2010-01-20 | 2015-04-01 | 上海市肿瘤研究所 | 表皮生长因子受体模拟表位肽及其应用 |
| CN102127147B (zh) * | 2010-01-20 | 2014-07-02 | 上海市肿瘤研究所 | 表皮生长因子受体模拟表位肽及其应用 |
| JP2013534515A (ja) | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体 |
| US9464136B2 (en) | 2010-08-20 | 2016-10-11 | Massachusetts Institute Of Technology | Antibody-based constructs directed against tyrosine kinase receptors |
| JP2014515753A (ja) | 2011-04-21 | 2014-07-03 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 新規な結合剤−薬物複合体（ａｄｃ）およびそれらの使用 |
| MX356550B (es) * | 2012-03-27 | 2018-06-01 | Green Cross Corp | Epitopes de antigeno de superficie de receptor de factor de crecimiento epidermico y uso de los mismos. |
| JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Ｅｇｆｒ結合性ペプチド |
| PL3086814T3 (pl) | 2013-12-23 | 2020-12-28 | Bayer Pharma Aktiengesellschaft | Koniugaty środka wiążącego (ADC) z inhibitorami KSP |
| MY178160A (en) | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| IL295906A (en) | 2014-03-21 | 2022-10-01 | Abbvie Inc | Anti-egfr antibodies and antibody drug conjugates |
| WO2016164833A1 (en) * | 2015-04-08 | 2016-10-13 | Nantomics, Llc | Cancer neoepitopes |
| RU2719033C2 (ru) | 2015-04-23 | 2020-04-16 | Нантомикс, Ллс | Способ получения фармацевтического агента для иммунотерапии рака |
| SG10201908685QA (en) | 2015-06-22 | 2019-10-30 | Bayer Pharma AG | Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| CN108701173A (zh) | 2015-10-12 | 2018-10-23 | 南托米克斯有限责任公司 | 用于发现预测对检查点抑制剂敏感的msi和新表位的系统、组合物和方法 |
| CN116059390A (zh) | 2016-03-24 | 2023-05-05 | 拜耳制药股份公司 | 具有酶促可裂解基团的细胞毒性活性物质的前药 |
| CN109310781B (zh) | 2016-06-15 | 2024-06-18 | 拜耳制药股份公司 | 具有ksp抑制剂和抗-cd123-抗体的特异性抗体-药物-缀合物(adc) |
| PE20191235A1 (es) | 2016-12-21 | 2019-09-11 | Bayer Pharma AG | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente |
| WO2018114804A1 (de) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren |
| KR20190099250A (ko) | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| WO2020174370A2 (en) | 2019-02-26 | 2020-09-03 | Janssen Biotech, Inc. | Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies |
| CN113993902B (zh) * | 2019-03-22 | 2025-03-14 | 瑟缇斯治疗私人有限公司 | 抗her2结合分子 |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JOP20220184A1 (ar) | 2020-02-12 | 2023-01-30 | Janssen Biotech Inc | علاج مصابي السرطان ممن لديهم طفرات تخطي c-Met إكسون14 |
| CN111647074B (zh) * | 2020-06-01 | 2023-12-19 | 皖南医学院 | 一种her3二聚化界面抗原肽、重组抗原肽、编码基因及其应用 |
| AR124681A1 (es) | 2021-01-20 | 2023-04-26 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
| EP4359440A1 (en) | 2021-06-22 | 2024-05-01 | Regeneron Pharmaceuticals, Inc. | Anti-egfrviii antibody drug conjugates and uses thereof |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE31006E (en) | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
| US3654090A (en) | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
| US4491632A (en) | 1979-10-22 | 1985-01-01 | The Massachusetts General Hospital | Process for producing antibodies to hepatitis virus and cell lines therefor |
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| EP0043718B1 (en) | 1980-07-07 | 1984-11-28 | National Research Development Corporation | Improvements in or relating to cell lines |
| US4341761A (en) | 1980-07-25 | 1982-07-27 | E. I. Du Pont De Nemours And Company | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon |
| US4466917A (en) | 1981-02-12 | 1984-08-21 | New York University | Malaria vaccine |
| US4493890A (en) | 1981-03-23 | 1985-01-15 | Miles Laboratories, Inc. | Activated apoglucose oxidase and its use in specific binding assays |
| US4451570A (en) | 1981-03-26 | 1984-05-29 | The Regents Of The University Of California | Immunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell line |
| US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
| US4399121A (en) | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
| US4427783A (en) | 1981-12-14 | 1984-01-24 | Hoffmann-La Roche Inc. | Immunoassay of thymosin α1 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4493795A (en) | 1983-10-17 | 1985-01-15 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US4943533A (en) * | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
| US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
| US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU633867B2 (en) | 1989-02-02 | 1993-02-11 | Eli Lilly And Company | Delivery of cytotoxic agents |
| AU639726B2 (en) * | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5459061A (en) * | 1990-01-26 | 1995-10-17 | W. Alton Jones Cell Science Center, Inc. | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor |
| WO1991016350A1 (en) | 1990-04-20 | 1991-10-31 | Ludwig Institute For Cancer Research | Aberrant, epidermal growth factor receptor dna, rna and protein forms and method |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU649275B2 (en) | 1990-11-06 | 1994-05-19 | Bristol-Myers Squibb Company | Prodrugs for beta-lactamase and uses thereof |
| ATE181575T1 (de) * | 1991-04-25 | 1999-07-15 | Chugai Pharmaceutical Co Ltd | Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| AU4663493A (en) | 1992-07-06 | 1994-01-31 | Hybritech Incorporated | Method for delivery of cytotoxic agents and components thereof |
| JP3720353B2 (ja) | 1992-12-04 | 2005-11-24 | メディカル リサーチ カウンシル | 多価および多重特異性の結合タンパク質、それらの製造および使用 |
| US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
| US6111166A (en) | 1994-09-19 | 2000-08-29 | Medarex, Incorporated | Transgenic mice expressing human Fcα and β receptors |
| ATE262586T1 (de) | 1994-11-28 | 2004-04-15 | Univ Jefferson | Fusion junction typ iii mutant egf rezeptor peptid-tumorvakzin |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US5708156A (en) | 1996-05-31 | 1998-01-13 | Ilekis; John V. | Epidermal growth factor receptor-like gene product and its uses |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US5942602A (en) | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
| NZ518477A (en) * | 1999-10-29 | 2004-10-29 | Genentech Inc | Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo |
| IL150592A0 (en) * | 2000-01-25 | 2003-02-12 | Genentech Inc | Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer |
| CA2418083A1 (en) | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
| US20100056762A1 (en) * | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| EP1392359B2 (en) * | 2001-05-11 | 2013-03-13 | Ludwig Institute for Cancer Research Ltd. | Specific binding proteins and uses thereof |
| MXPA03011365A (es) * | 2001-06-13 | 2005-03-07 | Genmab As | Anticuerpos monoclonales humanos para el receptor de factor de crecimiento epidermico (egfr). |
| CA2456236A1 (en) * | 2001-08-03 | 2003-02-20 | Commonwealth Scientific And Industrial Research Organisation | Methods of screening based on the egf receptor crystal structure |
| WO2003084998A1 (fr) * | 2002-04-11 | 2003-10-16 | Fuso Pharmaceutical Industries, Ltd. | Anticorps monoclonal neutralisant la megsine |
| US7767792B2 (en) | 2004-02-20 | 2010-08-03 | Ludwig Institute For Cancer Research Ltd. | Antibodies to EGF receptor epitope peptides |
| EP3042964A1 (en) * | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| ZA200704796B (en) * | 2004-12-07 | 2008-11-26 | Genentech Inc | Selecting patients for therapy with a HER inhibitor |
| WO2008033495A2 (en) | 2006-09-15 | 2008-03-20 | Life Science Pharmaceuticals | Method for detecting and treating skin disorders |
| US9090693B2 (en) * | 2007-01-25 | 2015-07-28 | Dana-Farber Cancer Institute | Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease |
| CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
| CN101896503B (zh) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2005
- 2005-02-17 US US11/060,646 patent/US7767792B2/en active Active
- 2005-02-18 AU AU2005216082A patent/AU2005216082B8/en not_active Expired
- 2005-02-18 WO PCT/US2005/005155 patent/WO2005081854A2/en not_active Ceased
- 2005-02-18 CA CA2556632A patent/CA2556632C/en not_active Expired - Lifetime
- 2005-02-18 KR KR1020067019405A patent/KR101280267B1/ko not_active Expired - Lifetime
- 2005-02-18 KR KR1020127010335A patent/KR101270443B1/ko not_active Expired - Lifetime
- 2005-02-18 ES ES05723258.9T patent/ES2536974T3/es not_active Expired - Lifetime
- 2005-02-18 JP JP2006554221A patent/JP2008501308A/ja active Pending
- 2005-02-18 EP EP05723258.9A patent/EP1722808B1/en not_active Expired - Lifetime
- 2005-02-18 EP EP12164335A patent/EP2514763A1/en not_active Withdrawn
-
2010
- 2010-01-29 US US12/657,919 patent/US8652473B2/en not_active Expired - Lifetime
- 2010-09-20 AU AU2010224335A patent/AU2010224335B2/en not_active Expired
-
2011
- 2011-12-15 JP JP2011274098A patent/JP6045147B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501308A5 (cg-RX-API-DMAC7.html) | ||
| US8492520B2 (en) | Binding epitopes for G250 antibody | |
| WO2017147742A1 (en) | Gfral receptor therapies | |
| US20240124549A1 (en) | Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors pd1 and pd-l1 | |
| EP2279413B1 (en) | Methods, antibodies and kits for detecting cerebrospinal fluid in a sample | |
| JP2010502984A (ja) | サンプル中の脳脊髄液を検出するための方法およびキット | |
| WO2004031238A2 (en) | Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics | |
| KR20120050530A (ko) | Ｅｇｆ 수용체 에피토프 펩타이드 및 이의 용도 | |
| JP2015516813A5 (cg-RX-API-DMAC7.html) | ||
| AU2005229072A1 (en) | BMP-3 propeptides and related methods | |
| US7744882B2 (en) | Soluble ErbB3 methods of detection and antibodies | |
| CA2912514A1 (en) | Method for predicting clinical effect of immunotherapy | |
| EP2267125B1 (en) | Cancer cell migration and cancer cell invasion inhibitor | |
| CA2340721A1 (en) | Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor | |
| KR20190064600A (ko) | Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드 | |
| AU9499898A (en) | Mutants of thyroid stimulating hormone and methods based thereon | |
| WO2009157919A1 (en) | SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER | |
| JP2007503820A (ja) | 細胞レセプタードメインを含むコイルドコイル融合タンパク質 | |
| US20080267961A1 (en) | SOLUBLE ErbB3 AND TREATMENT OF CANCER | |
| JP6187960B2 (ja) | がんの治療又は予防剤 | |
| US20060024314A1 (en) | Antibodies and cyclic peptides which bind CEA (carcinoembryonic antigens) and their use as cancer therapeutics | |
| CN107589262B (zh) | 用于检测乳腺癌的试剂盒 | |
| EP3161488B1 (en) | Method for diagnosing the risk of preneoplastic and neoplastic liver disease in subjects affected by hepatitis | |
| Phelps et al. | Development and characterization of monoclonal antibodies specific for amylin | |
| CN107531802A (zh) | 来自肝细胞生长因子/散射因子（hgf/sf）的kringle结构域的多聚体化合物 |